News & Articles

When: January 10, 2016 – January 11, 2016 (all-day) Where: San Francisco, CA, USA Who: Impel CEO, John Hoekman will be attending the 35th annual JPM Healthcare Conference ...

Development of neurological and mental health drugs often requires pre-clinical testing in multiple pre-clinical models to demonstrate efficacy and safety and to elucidate mechanisms. Drug delivery to the central nervous system (CNS) to target neurological diseases is particularly problematic because the blood-brain barrier (BBB) prevents most compounds from reaching the...

On April 8th, Impel's director of business development, Paul Jenkins, will be presenting a talk on "Intranasal Insulin for the Treatment of Alzheimer’s Disease" at the Nasal Drug Delivery Conference in London. His presentation is on April 8 at 11:30 am in the Nose-to-brain Transport session....

On April 6 Impel CSO, John Hoekman will be presenting a talk on "Intranasal Insulin for the Treatment of Alzheimer’s Disease" at the Neurotech conference in Boston. His talk will be on April 6 at 10:30 at the Treatments for Alzheimer's and Cognitive Disorders session.  ...